Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Koh

Showing results (111-120 of 144) with videos related to

Pageof 15
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
Multiplexed molecular profiling of lung cancer using pleural effusionHiroaki Akamatsu, Yasuhiro Koh, Hirotsugu Kenmotsu, et al.
Cancer Immunology, Immunotherapy : CII|January 17, 2022
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitorsYuhei Harutani, Yuichi Ozawa, Eriko Murakami, et al.
Journal of Medicinal Chemistry|September 15, 2009
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistanceArun K Ghosh, Sarang Kulkarni, David D Anderson, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2024
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancerAkihiro Tamiya, Mitsuo Osuga, Daijiro Harada, et al.
BMC Pulmonary Medicine|August 24, 2024
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance statusYoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, et al.
Cancer Medicine|April 5, 2025
Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational StudyAkihiro Tamiya, Yasuyuki Mizumori, Mitsuo Osuga, et al.
Translational Oncology|April 30, 2021
Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrationsMotohiro Izumi, Kenji Sawa, Jun Oyanagi, et al.
Clinical Lung Cancer|January 7, 2017
Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel SequencingMitsuhiro Isaka, Masakuni Serizawa, Hirotsugu Kenmotsu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 2, 2014
Identification of actionable mutations in malignant pleural mesotheliomaTakehito Shukuya, Masakuni Serizawa, Masaru Watanabe, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2011
Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumorsKyoichi Kaira, Masakuni Serizawa, Yasuhiro Koh, et al.
Pageof 15

Showing results (111-120 of 144) with videos related to

Sort By:
Pageof 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
Multiplexed molecular profiling of lung cancer using pleural effusionHiroaki Akamatsu, Yasuhiro Koh, Hirotsugu Kenmotsu, et al.
Cancer Immunology, Immunotherapy : CII|January 17, 2022
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitorsYuhei Harutani, Yuichi Ozawa, Eriko Murakami, et al.
Journal of Medicinal Chemistry|September 15, 2009
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistanceArun K Ghosh, Sarang Kulkarni, David D Anderson, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2024
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancerAkihiro Tamiya, Mitsuo Osuga, Daijiro Harada, et al.
BMC Pulmonary Medicine|August 24, 2024
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance statusYoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, et al.
Cancer Medicine|April 5, 2025
Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational StudyAkihiro Tamiya, Yasuyuki Mizumori, Mitsuo Osuga, et al.
Translational Oncology|April 30, 2021
Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrationsMotohiro Izumi, Kenji Sawa, Jun Oyanagi, et al.
Clinical Lung Cancer|January 7, 2017
Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel SequencingMitsuhiro Isaka, Masakuni Serizawa, Hirotsugu Kenmotsu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 2, 2014
Identification of actionable mutations in malignant pleural mesotheliomaTakehito Shukuya, Masakuni Serizawa, Masaru Watanabe, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2011
Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumorsKyoichi Kaira, Masakuni Serizawa, Yasuhiro Koh, et al.
Pageof 15